Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence

References

• Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27(9), 1485–1491 (2009).
   PubMed Web of Science ®Google Scholar
• Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol. 56(6), 1384–1391 (2012).
   PubMed Web of Science ®Google Scholar
• Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care 34(1), 216–219 (2011).
   PubMed Web of Science ®Google Scholar
• Yeh CJ, Chang HY, Pan WH. Time trend of obesity, the metabolic syndrome and related dietary pattern in Taiwan: from NAHSIT 1993-1996 to NAHSIT 2005–2008. Asia Pac. J. Clin. Nutr. 20(2), 292–300 (2011).
   PubMed Web of Science ®Google Scholar
• Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115(24), 5651–5661 (2009).
   PubMed Web of Science ®Google Scholar
• Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 332(6037), 1519–1523 (2011).
   PubMed Web of Science ®Google Scholar
• Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER–Medicare database. Hepatology 54(2), 463–471 (2011).
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348(17), 1625–1638 (2003).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126(2), 460–468 (2004).
   PubMed Web of Science ®Google Scholar
• Ohki T, Tateishi R, Sato T et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin. Gastroenterol. Hepatol. 6(4), 459–464 (2008).
   PubMed Web of Science ®Google Scholar
• Konishi I, Hiasa Y, Shigematsu S et al. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int. 29(8), 1194–1201 (2009).
   PubMedGoogle Scholar
• Park EJ, Lee JH, Yu GY et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140(2), 197–208 (2010).
   PubMed Web of Science ®Google Scholar
• Siegel AB, Lim EA, Wang S et al. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation 94(5), 539–543 (2012).
   PubMed Web of Science ®Google Scholar
• Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl Acad. Sci. USA 102(7), 2561–2566 (2005).
   PubMed Web of Science ®Google Scholar
• Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 140(1), 144–152 (2011).
   PubMedGoogle Scholar
• Athyros VG, Tziomalos K, Gossios TD et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376(9756), 1916–1922 (2010).
   PubMed Web of Science ®Google Scholar
• Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat. Rev. Cancer 5(12), 930–942 (2005).
   PubMed Web of Science ®Google Scholar
• Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7(6), 687–692 (2001).
   PubMed Web of Science ®Google Scholar
• Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 64(18), 6461–6468 (2004).
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol. 23(34), 8606–8612 (2005).
   PubMed Web of Science ®Google Scholar
• Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352(21), 2184–2192 (2005).
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367(19), 1792–1802 (2012).
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J. Clin. Oncol. 25(23), 3462–3468 (2007).
   PubMed Web of Science ®Google Scholar
• Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 295(1), 74–80 (2006).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136(5), 1601–1608 (2009).
   PubMed Web of Science ®Google Scholar
• Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Clin. Oncol. 30(6), 623–630 (2012).
   PubMed Web of Science ®Google Scholar
• Wu CY, Chen YJ, Ho HJ et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308(18), 1906–1914 (2012).
   PubMed Web of Science ®Google Scholar
• Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84(7), 886–891 (2001).
   PubMed Web of Science ®Google Scholar
• Graf H, Jüngst C, Straub G et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 78(1), 34–38 (2008).
   PubMed Web of Science ®Google Scholar
• Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Clin. Oncol. 31(12), 1514–1521 (2013).
   PubMed Web of Science ®Google Scholar
• Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig. Dis. Sci. 55(1), 190–195 (2010).
   PubMedGoogle Scholar
• Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144(2), 323–332 (2013).
   PubMed Web of Science ®Google Scholar
• Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53(3), 791–799 (2011).
   PubMed Web of Science ®Google Scholar
• Burza MA, Pirazzi C, Maglio C et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig. Liver Dis. 44(12), 1037–1041 (2012).
   PubMedGoogle Scholar
• Lipkin SM, Chao EC, Moreno V et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev. Res. (Phila.) 3(5), 597–603 (2010).
   PubMed Web of Science ®Google Scholar